Zenbexus FDA label names Hematogenix NGF in MRD efficacy evidence

Summary

FDA granted accelerated approval to the specified iberdomide combination on 13 August 2026.

The evidence

FDA granted accelerated approval to the specified iberdomide combination on 13 August 2026.

Label Table 4 reports MRD-negative complete response in 85/207 (41%) versus 44/213 (21%), p<0.0001.

The Table 4 footnote identifies a Hematogenix NGF assay at a 10^-5 threshold.

Interpretation and limitations

Drug approval is not assay approval or clearance.

The threshold is not a complete analytical validation dossier; these trial results do not establish interchangeability with other MRD assays.

What this means for laboratories

CFCM explainer

Trial endpoint → assay review → product label. Separate question → assay authorization.

CFCM schematic based on the cited regulatory documents. Alt text: distinction between trial assay review and assay authorization.

Source Date

August 13, 2026

Event date

August 13, 2026

Commercial Regulatory Status

Accelerated drug approval; assay clearance or approval not established

Primary source

Read the source →

An announcement is not proof of availability or authorisation. Interpret status within the stated jurisdiction and evidence boundary.

Editor and independence disclosure →

CFCM WEEKLY · EVERY SUNDAY

The science behind the signal, in your inbox.

Get evidence-led clinical flow cytometry news, original conference posters, figures from published papers, practical learning pills, an advanced quiz and the story of one CD marker each week. Free. No spam.

Get CFCM Weekly →

Complete the form and confirm the email we send you. Unsubscribe any time. Privacy policy.